Agenus has been granted a patent for antibodies that target CTLA-4 and PD-1 to enhance T cell activation in cancer patients. The method involves administering a therapeutic combination of specific antibodies. This innovation opens new possibilities for cancer treatment. GlobalData’s report on Agenus gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Agenus, Personalized cancer vaccines was a key innovation area identified from patents. Agenus's grant share as of May 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
Combination therapy for increasing t cell activation in cancer
A recently granted patent (Publication Number: US11993653B2) discloses a method for increasing T cell activation in cancer patients by administering a therapeutic combination of two isolated antibodies. The first antibody specifically binds to human CTLA-4, while the second antibody targets human PD-1. The antibodies are designed with specific amino acid sequences in their variable regions to enhance their efficacy in activating T cells. The method is particularly focused on treating various types of cancers, including metastatic or locally advanced solid tumors, cervical cancer, non-small cell lung cancer (NSCLC), and cutaneous squamous-cell carcinoma (cSCC), among others. The combination therapy is intended for use in cases where standard therapies are not available, or the cancer is refractory or has relapsed after standard treatments.
Furthermore, the patent details specific dosages and administration schedules for the antibodies, highlighting the importance of precise treatment regimens in achieving optimal T cell activation. The method also addresses scenarios where the cancer has relapsed after platinum-based chemotherapy or is in an advanced or metastatic stage. By targeting key immune checkpoint proteins, CTLA-4 and PD-1, the therapeutic combination aims to enhance the immune response against cancer cells, potentially offering new treatment options for patients with challenging cancer types. The patent underscores the significance of personalized medicine approaches in cancer treatment, tailoring the therapy to the specific characteristics of the patient's cancer and immune response.
To know more about GlobalData’s detailed insights on Agenus, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
